Federal Register / Vol. 89, No. 43 / Monday, March 4, 2024 / Notices 15577 

December 26, 2023. No comments were 

received. 

Obtaining Copies: Requesters may 

obtain a copy of the information 

collection documents from the GSA 

Regulatory Secretariat Division, by 

calling 202–501–4755 or emailing 

GSARegSec@gsa.gov. Please cite OMB 

Control No. 9000–0205, Implementation 

of Federal Acquisition Supply Chain 

Security Act (FASCSA) Orders. 

Janet Fry, 

Director, Federal Acquisition Policy Division, 

Office of Governmentwide Acquisition Policy, 

Office of Acquisition Policy, Office of 

Governmentwide Policy. 

[FR Doc. 2024–04505 Filed 3–1–24; 8:45 am] 

BILLING CODE 6820–EP–P 

UNITED STATES AGENCY FOR 

GLOBAL MEDIA 

Fiscal Year (FY) 2022 Service Contract 

Inventory Report & FY 2023 Planned 

Analysis 

AGENCY: United States Agency for 

Global Media. 

ACTION: Notice. 

SUMMARY: The United States Agency for 

Global Media (USAGM) announces the 

members of its FY 2022 Service Contract 

Inventory Report and FY 2023 Planned 

Analysis. 

ADDRESSES: USAGM Office of Contracts, 

330 Independence Ave. SW, 

Washington, DC 20237. 

FOR FURTHER INFORMATION CONTACT: 

Khilena Adhin, Acquisition Policy 

Branch Chief, at conpolicy@usagm.gov, 

202–920–2302. 

SUPPLEMENTARY INFORMATION: In 

accordance with section 743 of division 

C of the Consolidated Appropriations 

Act of 2010, the U.S. Agency for Global 

Media (USAGM) is publishing this 

notice to advise the public of the 

availability of its FY 2022 Service 

Contract Inventory Report and FY 2023 

Planned Analysis. They are available on 

the USAGM website, through the 

following link: https://www.usagm.gov/ 

our-work/strategy-and-results/strategicpriorities/research-reports/servicecontract-inventory/. The service contract 

inventory provides information on 

service contract actions over $25,000 

made in FY 2022. The information is 

organized by function to show how 

contracted resources are distributed 

throughout the Agency. The inventory 

has been developed in accordance with 

guidance on service contract inventories 

issued on November 5, 2010 and on 

December 19, 2011 by the Office of 

Management and Budget, Office of 

Federal Procurement Policy (OFPP). 

Dated: February 28, 2024. 

Armanda Matthews, 

Program Support Specialist, U.S. Agency for 

Global Media. 

[FR Doc. 2024–04475 Filed 3–1–24; 8:45 am] 

BILLING CODE 8610–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Meeting of the Clinical Laboratory 

Improvement Advisory Committee 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC) announces the 

following meeting for the Clinical 

Laboratory Improvement Advisory 

Committee (CLIAC). This is a virtual 

meeting. It is open to the public, limited 

only by the number of webcast lines 

available. Time will be available for 

public comment, and the public is also 

welcome to submit written comments in 

advance of the meeting (see the public 

participation section below). 

DATES: The meeting will be held on 

April 10, 2024, from 10 a.m. to 6 p.m., 

EDT. 

ADDRESSES: This is a virtual meeting. 

Meeting times are tentative and subject 

to change. The confirmed meeting 

times, agenda items, and meeting 

materials, including instructions for 

accessing the live meeting broadcast, 

will be available on the CLIAC website 

at https://www.cdc.gov/cliac. Check the 

website on the day of the meeting for 

the web conference link. 

FOR FURTHER INFORMATION CONTACT: 

Heather Stang, M.S., Senior Advisor for 

Clinical Laboratories, Division of 

Laboratory Systems, Center for 

Laboratory Systems and Response, 

Office of Laboratory Science and Safety, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, 

Mailstop V24–3, Atlanta, Georgia 

30329–4027. Telephone: (404) 498– 

2769; Email: HStang@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The Clinical Laboratory 

Improvement Advisory Committee 

(CLIAC) is charged with providing 

scientific and technical advice and 

guidance to the Secretary, Department 

of Health and Human Services; the 

Assistant Secretary for Health; the 

Director, Centers for Disease Control 

and Prevention (CDC); the 

Commissioner, Food and Drug 

Administration (FDA); and the 

Administrator, Centers for Medicare & 

Medicaid Services (CMS). The advice 

and guidance pertain to general issues 

related to improvement in clinical 

laboratory quality and laboratory 

medicine and specific questions related 

to possible revision of the Clinical 

Laboratory Improvement Amendments 

of 1988 (CLIA) standards. Examples 

include providing guidance on studies 

designed to improve quality, safety, 

effectiveness, efficiency, timeliness, 

equity, and patient-centeredness of 

laboratory services; revisions to the 

standards under which clinical 

laboratories are regulated; the impact of 

proposed revisions to the standards on 

medical and laboratory practice; and the 

modification of the standards and 

provision of non-regulatory guidelines 

to accommodate technological 

advances, such as new test methods, the 

electronic transmission of laboratory 

information, and mechanisms to 

improve the integration of public health 

and clinical laboratory practices. 

Matters to be Considered: The agenda 

will include agency updates from CDC, 

CMS, and FDA. Presentations and 

CLIAC discussions will focus on the 

applicability of CLIA personnel 

requirements to preanalytic testing, the 

role of artificial intelligence and 

machine learning in the clinical 

laboratory, and the use of clinical 

standards to improve laboratory quality. 

Agenda items are subject to change as 

priorities dictate. 

Public Participation 

It is the policy of CLIAC to accept 

written public comments and provide a 

brief period for oral public comments 

pertinent to agenda items. 

Oral Public Comment: Public 

comment periods for each agenda item 

are scheduled immediately prior to the 

Committee discussion period for that 

item. In general, each individual or 

group requesting to present an oral 

comment will be limited to a total time 

of five minutes (unless otherwise 

indicated). Speakers should email 

CLIAC@cdc.gov or notify the contact 

person above (see FOR FURTHER

INFORMATION CONTACT) at least five 

business days prior to the meeting date. 

Written Public Comment: CLIAC 

accepts written comments until the date 

of the meeting (unless otherwise stated). 

However, it is requested that comments 

be submitted at least five business days 

prior to the meeting date so that the 


khammond on DSKJM1Z7X2PROD with NOTICES
15578 Federal Register / Vol. 89, No. 43 / Monday, March 4, 2024 / Notices 

comments may be made available to the 

Committee for their consideration and 

public distribution. Written comments 

should be submitted by email to 

CLIAC@cdc.gov or to the contact person 

above. All written comments will be 

included in the meeting minutes posted 

on the CLIAC website. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–04432 Filed 3–1–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Award of a Sole Source 

Cooperative Agreement To Fund 

Uganda National Health Laboratories 

and Diagnostic Services (NHLDS) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), located 

within the Department of Health and 

Human Services (HHS), announces the 

award of approximately $10,000,000, for 

Year 1 funding to NHLDS. The award 

will strengthen laboratory systems in 

Uganda by contributing to the 

attainment of HIV epidemic control and 

establishing sustainable and integrated 

systems for quality assured disease 

diagnostics, monitoring, and 

surveillance. Funding amounts for years 

2–5 will be set at continuation. 

DATES: The period for this award will be 

September 30, 2024, through September 

29, 2029. 

FOR FURTHER INFORMATION CONTACT: 

Christina Mwangi, Center for Global 

Health, Centers for Disease Control and 

Prevention, US Embassy Kampala, US 

Centers for Disease Control and 

Prevention, 1577 Ggaba Road, 

Telephone: 256772139023, Email: 

mwn0@cdc.gov. 

SUPPLEMENTARY INFORMATION: The sole 

source award will strengthen Uganda’s 

access to quality laboratory services 

during the scale up of HIV prevention, 

care, and treatment by supporting 

implementation of the Uganda National 

Health Laboratory Services (UNHLS) 

Policy II (2016) and its Strategic Plan 

(2020–2025). 

NHLDS is in a unique position to 

conduct this work, as it is the primary 

stakeholder of laboratory-related policy 

development, strategic planning, and 

resources mobilization for the Ministry 

of Health (MOH). Additionally, NHLDS 

directly houses and manages the Central 

Public Health Reference Laboratory 

(CPHL) which is the national reference 

laboratory for HIV early infant diagnosis 

and viral load, national microbiology 

reference laboratory, national 

Tuberculosis (TB) reference laboratory, 

the national laboratory biorepository 

and national equipment calibration 

center. Furthermore, the NHLDS is the 

primary coordinator of the integrated 

national laboratory specimen 

transportation network that handles 

both HIV, TB and outbreak specimen 

referral across the country. 

Summary of the Award 

Recipient: Uganda National Health 

Laboratories and Diagnostic Services 

(NHLDS). 

Purpose of the Award: The purpose of 

this award is to strengthen laboratory 

systems in Uganda by contributing to 

the attainment of HIV epidemic control 

and establishing sustainable and 

integrated systems for quality assured 

disease diagnostics, monitoring, and 

surveillance. 

Amount of Award: For NHLDS, the 

approximate year 1 funding amount will 

be $10,000,000 in Federal Fiscal Year 

(FYY) 2024 funds, subject to the 

availability of funds. Funding amounts 

for years 2–5 will be set at continuation. Authority: This program is authorized 

under Public Law 108–25 (the United 

States Leadership Against HIV AIDS, 

Tuberculosis and Malaria Act of 2003) 

[22 U.S.C. 7601, et seq.] and Public Law 

110–293 (the Tom Lantos and Henry J. 

Hyde United States Global Leadership 

Against HIV/AIDS, Tuberculosis, and 

Malaria Reauthorization Act of 2008), 

and Public Law 113–56 (PEPFAR 

Stewardship and Oversight Act of 2013). Period of Performance: The period for 

this award will be September 30, 2024, 

through September 29, 2029. 

Dated: February 26, 2024. 

Jamie Legier, 

Acting Director, Office of Grants Services, 

Centers for Disease Control and Prevention. 

[FR Doc. 2024–04399 Filed 3–1–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Solicitation of Nominations for 

Appointment to the Communications 

and Public Engagement Workgroup 

(CPEW) of the Advisory Committee to 

the Director (ACD), CDC 

ACTION: Notice. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), within 

the Department of Health and Human 

Services (HHS), is seeking nominations 

for membership to the Communications 

and Public Engagement Workgroup 

(CPEW) of the Advisory Committee to 

the Director, CDC. The CPEW 

workgroup consists of approximately 15 

members who are experts in the fields 

associated with communications, 

including public relations, health 

communication, risk communication, 

communication research, and 

marketing; community and partner 

engagement; public health science and 

practice, including implementation; and 

behavioral science/behavior change 

campaigns. 

DATES: Nominations for membership on 

the CPEW workgroup must be received 

no later than March 28, 2024. Late 

nominations will not be considered for 

membership. 

ADDRESSES: All nominations (cover 

letters and curriculum vitae) should be 

emailed to ACDirector@cdc.gov with the 

subject line: ‘‘Nomination for CDC ACD 

Communications and Public 

Engagement Workgroup.’’ 

FOR FURTHER INFORMATION CONTACT: Kate 

Galatas, MPH, Senior Communications 

Specialist, Office of Communications, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road (MS 

H21–11), Atlanta, GA 30329–4027, 

Telephone: (404) 639–2064; Email: 

ACDirector@cdc.gov. 

SUPPLEMENTARY INFORMATION:

Background: The purpose of the ACD, 

CDC Advisory Committee to the 

Director shall (1) make 

recommendations to the Director 

regarding ways to prioritize the 

activities of the agency in alignment 

with the CDC Strategic Plan required 

under section 305(c); H.R. 2617–1252; 

(2) advise on ways to achieve or 

improve performance metrics in relation 

to the CDC Strategic Plan, and other 

relevant metrics, as appropriate; (3) 

provide advice and recommendations 

on the development of the Strategic 

Plan, and any subsequent updates, as 


khammond on DSKJM1Z7X2PROD with NOTICES